Terms ending in 2039
Every in-force patent on AstraZeneca AB's record whose computed term ends in 2039, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 10,957,435 | Computer System and Method for Generating Trigger Alerts to Maximize Interactions with Healthcare Providers In force · High confidence | AstraZeneca AB | In force | High confidence | |
| US 11,420,984 | Arginase Inhibitors and Methods of Use Thereof In force · High confidence | AstraZeneca AB | In force | High confidence | |
| US 11,912,727 | Arginase Inhibitors and Methods of Use Thereof In force · Medium confidence | AstraZeneca AB | In force | Medium confidence | |
| US 12,195,485 | Arginase Inhibitors and Methods of Use Thereof In force · High confidence | AstraZeneca AB | In force | High confidence | |
| US 12,201,638 | Pharmaceutical Compositions Comprising (2S)-N-{(1S)-1-Cyano-2-[4-(3-Methyl-2-OXO-2,3-Dihydro-1,3-Benzoxazol-5-yl)PHENYL]ETHYL}-1,4- OXAZEPANE-2-Carboxamide In force · Medium confidence | AstraZeneca AB | In force | Medium confidence | |
| US 11,479,539 | Small Molecule Modulators of the BTB Domain of KEAP1 In force · Medium confidence | MedImmune Limited | In force | Medium confidence | |
| US 11,798,661 | Methods for Lowering Blood Pressure with a Dihydropyridine-Type Calcium Channel Blocker Pharmaceutical Composition In force · High confidence | AstraZeneca UK Limited | In force | High confidence | |
| US 11,149,029 | Novel Salts of Ijak Inhibitors and Methods of Using the Same In force · High confidence | AstraZeneca AB | In force | High confidence | |
| US 11,826,376 | Methods of Treating Heart Failure with Preserved Ejection Fraction Employing Dapagliflozin and Compositions Comprising the Same In force · High confidence | AstraZeneca AB | In force | High confidence | |
| US 12,472,194 | Methods of Treating Heart Failure with Preserved Ejection Fraction Employing Dapagliflozin and Compositions Comprising the Same In force · High confidence | AstraZeneca AB | In force | High confidence | |
| 3 more term ends in 2039 · Pro | |||||
10 of 13 patents shown. Soonest term end first, then patent number.
Pro members see all 13.
10 of these are in force and held by AstraZeneca AB.
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.